DURECT Corporation (DRRX)

US — Healthcare Sector
Peers: SHPH  MNK  ORGO  LSDI  ALIM  TKNO  AGRX  SNOA  EGRX  LFCR  RDHL  TARO  COLL  NBIX  DCPH  IRWD  ALKS  AVDL  AQST  EVOK  ADMP  GHSI  ACRX 

Automate Your Wheel Strategy on DRRX

With Tiblio's Option Bot, you can configure your own wheel strategy including DRRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DRRX
  • Rev/Share 0.0169
  • Book/Share 0.1867
  • PB 3.3839
  • Debt/Equity 0.3423
  • CurrentRatio 1.2266
  • ROIC -2.2289

 

  • MktCap 19606506.0
  • FreeCF/Share -0.5113
  • PFCF -1.2354
  • PE -3.9907
  • Debt/Assets 0.1381
  • DivYield 0
  • ROE -0.9279

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript
DRRX
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Neutral

DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Co-Founder, Chief Executive Officer, President, Director Norman Sussman - Chief Medical Officer WeiQi Lin - Executive Vice President, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer & Company Karl Burns - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the DURECT Corporation Fourth Quarter and Full-Year 2024 Earnings Conference Call.

Read More
image for news DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
DRRX
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative

Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.27 per share a year ago.

Read More
image for news Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates

About DURECT Corporation (DRRX)

  • IPO Date 2000-09-28
  • Website https://www.durect.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Dr. James E. Brown D.V.M.
  • Employees 21
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.